Drug Profile
Research programme: monoclonal antibody therapeutics - PDL BioPharma/Trellis BioScience
Latest Information Update: 10 Sep 2008
Price :
$50
*
At a glance
- Originator PDL BioPharma; Trellis Bioscience
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 10 Sep 2008 No development reported - Preclinical for Immunological disorders in USA (Parenteral)
- 18 Jan 2007 Preclinical trials in Immunological disorders in USA (Parenteral)